Summary & Overview
HCPCS C9023: Injection, Testosterone Undecanoate, 1 mg
HCPCS Level II code C9023 denotes an injection of testosterone undecanoate, 1 mg, an injectable formulation used for testosterone replacement therapy. Nationally, accurate coding for testosterone injections influences clinical documentation, pharmacy and medical benefit coordination, and payer coverage determinations for hormone therapy.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on the clinical service represented by the code, the usual sites where the injection is administered, and what to expect in terms of coverage landscapes and billing considerations at a national level.
This publication provides benchmarks for utilization and reimbursement patterns, notes recent policy updates affecting hormone therapy coverage, and situates C9023 within the broader clinical context of testosterone replacement. It is intended for revenue cycle leaders, billing professionals, and clinical managers seeking clarity on coding, site-of-service implications, and payer alignment for injectable testosterone therapy.
Billing Code Overview
HCPCS Level II code C9023 represents an injection of testosterone undecanoate, 1 mg. This service is an injectable hormone therapy typically administered to patients requiring testosterone replacement or supplementation.
Service type: Injection / Drug Administration
Typical site of service: Outpatient clinic, physician office, or infusion center
Data not available in the input for payer-specific coverage, modifiers, associated taxonomies, ICD-10 diagnoses, related codes, and service line.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult male with diagnosed hypogonadism due to primary testicular failure or secondary hypogonadotropic hypogonadism presenting for depot testosterone therapy. The patient has laboratory-confirmed low serum total testosterone on at least two morning measurements, symptoms such as decreased libido, fatigue, and low muscle mass, and no contraindications to testosterone. During the clinic visit, the prescriber documents indication, reviews contraindications (prostate cancer history, elevated hematocrit), obtains baseline labs (PSA, hematocrit, liver function), and elects intramuscular long‑acting testosterone undecanoate formulation. The service includes medication preparation and administration of C9023 (injection, testosterone undecanoate, 1 mg) supplied by the facility or pharmacy; the clinician documents route (intramuscular), dose, lot number, and patient tolerance. Typical workflow steps: patient check-in and vitals, medication reconciliation, informed discussion of risks and benefits, baseline lab review, administration by a qualified clinician (e.g., endocrinology, urology, primary care), post‑injection observation for adverse reaction, and scheduling of follow‑up dosing and monitoring labs. Typical dosing intervals and monitoring are managed per product labeling and specialty protocols.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure |